Ennov

Ennov is a SaaS-based compliance software vendor founded in 1999 by Olivier Paris and headquartered in Paris, France. The company provides quality management, clinical trial information, regulatory content, information management, and pharmacovigilance solutions exclusively for the life sciences industry.

Ennov serves 500+ customers globally with 250,000 users total, ranging from pharmaceutical companies to biotechnology companies. Named customers include Boehringer Ingelheim, Kenvue (formerly Johnson & Johnson Consumer Products), and Viatris. A top 25 pharmaceutical company selected Ennov for Global RIM implementation.

The company employs 220 employees across three continents (as of 2023) with presence in Paris, Basel, Boston, and India. PitchBook reports 159 employees as of 2025. Ennov experienced 30% growth in 2022.

Ennov's product portfolio includes quality management, regulatory information management (RIM), clinical trial information management, and pharmacovigilance solutions. The company was mentioned in Gartner's 2019 Market Guide for Life Science RIM Solutions and identified as a new-generation vendor capable of providing holistic end-to-end RIM solutions.

Ennov is privately funded with seed round investment from Windcrest Partners. The company acquired RIM solution provider Samarind to strengthen its regulatory capabilities.

Ennov is exclusively focused on the life sciences industry with 500+ customers and 250,000 users total. The company serves pharmaceutical companies ranging from multinational pharmaceutical organisations to biotechnology companies.

Named pharmaceutical customers include Boehringer Ingelheim, Kenvue (formerly Johnson & Johnson Consumer Products), and Viatris. A top 25 pharmaceutical company selected Ennov for Global RIM implementation.

Ennov's product portfolio is purpose-built for life sciences regulatory and quality operations including quality management, regulatory information management (RIM), clinical trial information management, and pharmacovigilance solutions. The company was mentioned in Gartner's 2019 Market Guide for Life Science RIM Solutions and identified as a new-generation vendor capable of providing holistic end-to-end RIM solutions.

Ennov's acquisition of RIM solution provider Samarind strengthened the company's regulatory capabilities. The SaaS-based platform approach provides compliance solutions designed specifically for regulated life sciences environments.

Ennov is privately funded with seed round investment from institutional investor Windcrest Partners. Specific funding amounts and revenue are not publicly disclosed.

The company experienced 30% growth in 2022. Ennov has acquired RIM solution provider Samarind to strengthen regulatory capabilities and expand product portfolio.

Ennov serves 500+ customers globally with 250,000 total users, ranging from pharmaceutical companies to biotechnology companies. A top 25 pharmaceutical company selected Ennov for Global RIM implementation.

Ennov provides a SaaS-based compliance platform for life sciences with solutions spanning quality management, regulatory affairs, clinical operations, and pharmacovigilance.

The product portfolio includes: - Quality Management: Quality and compliance management solutions - Regulatory Information Management (RIM): Purpose-built RIM application based on Ennov Process for managing therapeutic product details, registrations, submissions, correspondence, and commitments - Clinical Trial Information: Clinical trial information management - Pharmacovigilance: Safety and pharmacovigilance solutions - Information Management: Content and information management capabilities

Ennov RIM is built on the Ennov Process platform, providing process-driven workflows, automatic email notifications, real-time status updates, and dashboard reporting with querying and visual output. The platform supports portfolio management across small molecule therapies, large molecule therapies, medical devices, drug-device combinations, and nutritionals/supplements.

All solutions are delivered as 100% web-based SaaS applications with configurable user interfaces designed for life sciences professionals. The platform approach enables integrated regulatory, quality, and clinical operations management.

Ennov operates on a SaaS-based cloud platform model. Technology partners, integration-ecosystem details, and implementation-partner networks are undisclosed.

Ennov acquired RIM solution provider Samarind, expanding its regulatory capabilities and product portfolio.

Ennov provides implementation support and professional services for SaaS platform deployments across quality management, regulatory information management, clinical, and pharmacovigilance solutions.

Implementation services include system configuration, workflow customisation, user training, and deployment support. The platform's configurable nature supports adaptation to organisational processes and regulatory requirements.

With offices in Paris, Basel, Boston, and India, Ennov provides regional support across Europe, North America, and Asia. The company had 220 employees across three continents as of 2023.

Support availability (24/7, SLA commitments), customer success programmes, user community resources, and certification programmes are undisclosed.

Ennov was mentioned in Gartner's 2019 Market Guide for Life Science RIM Solutions and identified as a new-generation vendor capable of providing holistic end-to-end RIM solutions.

Founded in 1999 by Olivier Paris, Ennov has 26 years of history serving the life sciences industry.

Named customers include Boehringer Ingelheim, Kenvue (formerly Johnson & Johnson Consumer Products), and Viatris. A top 25 pharmaceutical company selected Ennov for Global RIM implementation.

Ennov acquired RIM solution provider Samarind, strengthening its regulatory capabilities. The company reported 30% growth in 2022.

Certifications (ISO 9001, ISO 27001, SOC 2), industry awards, leadership-team backgrounds, and thought-leadership programmes are undisclosed.

Ennov's website provides product information, solution descriptions, and a company overview, in English and French language versions serving European and global markets.

The company's market presence is primarily European-focused with headquarters in Paris, France and an additional office in Basel, Switzerland. North American presence includes a Boston, MA office. Asian presence is through an India office.

Ennov has 500+ customers and 250,000 users globally in life sciences compliance software. The company reported 30% growth in 2022.

Ennov was named a new-generation RIM vendor in Gartner's 2019 Market Guide. Named pharmaceutical customers include Boehringer Ingelheim, Kenvue, and Viatris.

Press-release frequency, social-media activity, content-marketing programmes, and industry-conference participation are undisclosed. North American market visibility is more limited than the company's European presence.